Drug Trial Radar · NCT05546853
Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Mar 28, 2023
Primary completion
Dec 9, 2024
Study completion Jun 16, 2025
Sponsor
- Lead sponsor
- University Hospital, GrenobleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- NETRIS Pharma
- First posted
- Sep 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will assess the safety of the association of NP137 with the standard of care mFOLFIRINOX in the treatment of locally advanced pancreatic ductal adenocarcinoma.The study drug which is tested is the NP137 in association with mFOLFIRINOX to allow a better tumor response as well as better survival outcomes with an acceptable safety.
Conditions
- Pancreatic Ductal Adenocarcinoma
Interventions
NP137Drug
NP137 will be administrated at the first day of each cycle (CnD1) of 14 days as an IV infusion at 9 or 14 mg/kg.
OxaliplatinDrug
Oxaliplatin will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 85 mg/m²
IrinotecanDrug
Irinotecan will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 150 mg/m²
Calcium levofolinateDrug
Calcium levofolinate will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 100 mg/m²
5 FUDrug
5 FU will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 2400 mg/m2 as a continuous intravenous infusion over 46 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Proportion of patients experiencing adverse eventsTime frame: At 6 months
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
CHU de BORDEAUX
Bordeaux, France
CHRU Lille
Lille, France
Hôpital Privé Jean Mermoz
Lyon, France
AP-HP Pitié Salpetrière
Paris, France
CHU Poitiers
Poitiers, France
CHU de REIMS
Reims, France
CHU Rennes
Rennes, France
CHU St Etienne
Saint-Etienne, France
CHU de GRENOBLE ALPES
Grenoble, Alpes, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.